5
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T39671 | MOG (89-113), human | ||
MOG (89-113), human is a peptide fragment of human myelin oligodendrocyte glycoprotein. | |||
T39110 | MOG (35-55), human | ||
MOG (35-55), human, a constituent of central nervous system myelin, is distinguishable from mMOG (35-55) due to a proline-to-serine substitution at position 42. It possesses immunogenic properties and is partially cross-... | |||
T83695 | MOG Peptide (human, bovine) acetate | Myelin Oligodendrocyte Glycoprotein Peptide | |
Myelin oligodendrocyte glycoprotein (MOG) peptide, a truncated form of MOG located on the extracellular myelin sheath surface, interacts with antigen serotype HLA-DR2 to mitigate effects of ischemic stroke induced by mid... | |||
T7657 | Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat | MOG (35-55) | Others |
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) is a truncated peptide derived from the human Myelin Oligodendrocyte Glycoprotein (MOG). | |||
T83688 | R 715 TFA | [Ac-Lys-[D-βNal7,Ile8]des-Arg9]-BK,Ac-Lys-Arg-Pro-Pro-Gly-Phe-Ser-D2Nal-Ile-OH | |
R 715, a bradykinin B1 receptor antagonist, inhibits contractions in isolated human umbilical cords that express bradykinin B1 receptors (pA2 = 8.49). When administered at doses of 200, 400, and 600 µg/kg, R 715 enhances... |